Drug developer Repligen said Monday that a federal court in Massachusetts refused to dismiss its claims in a patent infringement lawsuit against the drugmaker ImClone. In its motion for summary judgment, ImClone had argued that Repligen's claims should be dismissed because a patent in question had been exhausted. Repligen alleges that ImClone's production of the cancer drug Erbitux infringes a patent that is owned by Massachusetts Institute of Technology and is licensed exclusively to Repligen.
August 01, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Drug developer Repligen Corp. said Monday that a federal court refused to dismiss its claims in patent infringement lawsuit against the drugmaker ImClone Systems Inc.
The company said the U.S. District Court in Massachusetts declined to issue a summary judgment requested by ImClone. In its motion, ImClone had argued that that Repligen’s claims should be dismissed because a patent in question had been exhausted.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
